Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.55 |
| ▸ | PPARA | Q07869 | 3/20 | 0.53 |
| ▸ | PPARG | P37231 | 1/20 | 0.53 |
| ▸ | FBP1 | P09467 | 6/20 | 0.50 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | MMP14 | P50281 | 1/20 | 0.47 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.46 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.45 |
| ▸ | KMO | O15229 | 1/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4028110 | 0.86 | CYP11B2 (0.51) | CYP1A2CYP3A4MKNK1MKNK2CYP19A1 | |
| SCHEMBL1969926 | 0.86 | PPARA (0.56) | GRM2PPARAPPARGFBP1ABCB11 | |
| SCHEMBL3484032 | 0.82 | PPARA (0.57) | GRM2PPARAPPARGFBP1ABCB11 | |
| SCHEMBL27564026 | 0.79 | MMP2 (0.48) | MMP2MMP13MMP14MKNK1MKNK2 | |
| SCHEMBL418047 | 0.78 | PPARA (0.53) | GRM2PPARAPPARGFBP1ABCB11 | |
| SCHEMBL3484509 | 0.78 | PPARA (0.56) | GRM2PPARAPPARGFBP1ABCB11 | |
| SCHEMBL20730087 | 0.77 | PPARA (0.64) | GRM2PPARAPPARGFBP1ABCB11 | |
| SCHEMBL197882 | 0.77 | PPARA (0.64) | GRM2PPARAPPARGFBP1ABCB11 | |
| SCHEMBL23582194 | 0.76 | PPARA (0.51) | GRM2PPARAPPARGFBP1ABCB11 | |
| SCHEMBL31357627 | 0.76 | PPARA (0.51) | GRM2PPARAPPARGFBP1ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567493-B1 | PHENYL SUBSTITUTED PIPERIDINE COMPOUNDS FOR USE AS PPAR ACTIVATORS | PFIZER PROD INC (US) | 2009-03-18 | — | — | EP | disclosed |
| US-20070191429-A1 | PPAR ACTIVATORS | PFIZER INC. (US) | 2007-08-16 | — | — | US | disclosed |
| US-7199243-B2 | Piperidine compounds useful as PPAR activators | PFIZER INC. (US) | 2007-04-03 | — | — | US | disclosed |
| EP-1567493-A1 | PHENYL SUBSTITUTED PIPERIDINE COMPOUNDS FOR USE AS PPAR ACTIVATORS | Pfizer Products Inc. (US) | 2005-08-31 | — | — | EP | disclosed |
| US-20040157885-A1 | PPAR activators | PFIZER INC | 2004-08-12 | — | — | US | disclosed |
| WO-2004048334-A1 | PHENYL SUBSTITUTED PIPERIDINE COMPOUNDS FOR USE AS PPAR ACTIVATORS | PFIZER PRODUCTS INC. (US) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191429-A1 | PPAR ACTIVATORS | PPARA, PPARG, PPARD | GRM2 1015/4885PPARA 1/4885PPARG 2/4885 |
| US-20040157885-A1 | PPAR activators | PPARA, PPARG, PPARD | GRM2 1015/4885PPARA 1/4885PPARG 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.